Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)

被引：0

作者：

Hideki Kato

Masaomi Nangaku

Hideki Hirakata

Takashi Wada

Terumasa Hayashi

Hiroshi Sato

Yasushi Yamazaki

Takao Masaki

Tatsuo Kagimura

Hiroyasu Yamamoto

Hiroki Hase

Masahiro Kamouchi

Enyu Imai

Kyoichi Mizuno

Manabu Iwasaki

Tadao Akizawa

Yoshiharu Tsubakihara

Shoichi Maruyama

Ichiei Narita

机构：

[1] The University of Tokyo Graduate School of Medicine,Division of Nephrology and Endocrinology

[2] Fukuoka Renal Clinic,Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences

[3] Kanazawa University,Department of Kidney Disease and Hypertension

[4] Osaka General Medical Centre,Division of Clinical Pharmacology and Therapeutics

[5] Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences,Department of Nephrology and Rheumatology

[6] Kagawa Prefectural Central Hospital,Department of Nephrology

[7] Hiroshima University Hospital,Department of Internal Medicine

[8] Translational Research Informatics Center,Division of Nephrology

[9] Foundation Biomedical Research and Innovation,Department of Health Care Administration and Management, Graduate School of Medical Sciences

[10] Atsugi City Hospital,Nakayamadera Imai Clinic, Takarazuka, Hyogo, Department of Nephrology

[11] Toho University Ohashi Medical Center,Department of Computer and Information Science

[12] Kyushu University,Division of Nephrology, Department of Medicine

[13] Fujita Health University Toyoake,Course of Safety Management in Health Care Sciences, Graduate School of Health Care Sciences

[14] Mitsukoshi Health and Welfare Foundation,Department of Nephrology

[15] Seikei University,Division of Clinical Nephrology and Rheumatology

[16] Showa University School of Medicine,undefined

[17] Jikei Institute,undefined

[18] Nagoya University Graduate School of Medicine,undefined

[19] Niigata University Graduate School of Medical and Dental Sciences,undefined

来源：

Clinical and Experimental Nephrology | 2018年 / 22卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：85 / 86

页数：1

共 50 条

[21] Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa
Molina, M
Hernández, MAG
Navarro, MJ
Silva, FP
Cacho, M
De Gracia, MC
NEFROLOGIA, 2004, 24 (01): : 54 - 59
[22] Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease
Dean, BB
Dylan, M
Gano, A
Knight, K
Ofman, JJ
Levine, BS
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (07) : 981 - 987
[23] Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients
Evans, Marie
Carrero, Juan-Jesus
Bellocco, Rino
Barany, Peter
Qureshi, Abdul R.
Seeberger, Astrid
Jacobson, Stefan H.
Hylander-Rossner, Britta
Rotnitzky, Andrea
Sjolander, Arvid
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (11) : 1892 - 1901
[24] Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study
Tsuruya, Kazuhiko
Hayashi, Terumasa
Yamamoto, Hiroyasu
Hase, Hiroki
Nishi, Shinichi
Yamagata, Kunihiro
Nangaku, Masaomi
Wada, Takashi
Uemura, Yukari
Ohashi, Yasuo
Hirakata, Hideki
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (05) : 456 - 466
[25] Improvement of anemia by erythropoiesis - stimulating agents suppresses the progression of left ventricular hypertrohpy in patients with chronic kidney disease
Suzuki, M.
Akaishi, M.
Hada, Y.
Hiroe, M.
Tsubakihara, Y.
Akizawa, T.
EUROPEAN HEART JOURNAL, 2008, 29 : 755 - 755
[26] Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study
Kazuhiko Tsuruya
Terumasa Hayashi
Hiroyasu Yamamoto
Hiroki Hase
Shinichi Nishi
Kunihiro Yamagata
Masaomi Nangaku
Takashi Wada
Yukari Uemura
Yasuo Ohashi
Hideki Hirakata
Clinical and Experimental Nephrology, 2021, 25 : 456 - 466
[27] High Target Hemoglobin With Erythropoiesis-Stimulating Agents Has Advantages in the Renal Function of Non-Dialysis Chronic Kidney Disease Patients
Tsubakihara, Yoshiharu
Gejyo, Fumitake
Nishi, Shinichi
Iino, Yasuhiko
Watanabe, Yuzou
Suzuki, Masashi
Saito, Akira
Akiba, Takashi
Hirakata, Hideki
Akizawa, Tadao
THERAPEUTIC APHERESIS AND DIALYSIS, 2012, 16 (06) : 529 - 540
[28] Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Dialysis-Dependent Patients with Anaemia of Chronic Kidney Disease: A Retrospective Observational Study
Atzinger, Christopher
Arens, Hans-Juergen
Neri, Luca
Arkossy, Otto
Garbelli, Mario
Jiletcovici, Alina
Snijder, Robert
Leyland, Kirsten
Khalife, Najib
Ali, Mahmood
Feuersenger, Astrid
ADVANCES IN THERAPY, 2025, 42 (01) : 471 - 489
[29] BENEFICIAL DOSE CONVERSION FROM OTHER ERYTHROPOIESIS-STIMULATING AGENTS TO CERA IN HAEMODIALYSIS AND NOT IN DIALYSIS PATIENTS WITH ANEMIA SECONDARY TO CHRONIC KIDNEY DISEASE IN CLINICAL PRACTICE: MINERVA STUDY
Cases, A.
Portoles, J.
Calls, J.
Martinez-Castelao, A.
Munar, M. A.
Segarra, A.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 359 - 359
[30] Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective
Gauthier-Loiselle, Marjolaine
Michalopoulos, Steven N.
Cloutier, Martin
Serra, Elizabeth
Bungay, Rebecca
Szabo, Erika
Guerin, Annie
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (12): : 1703 - 1713

← 1 2 3 4 5 →